{Reference Type}: Case Reports
{Title}: A Novel Mutation in a Patient with Hyperparathyroidism-Jaw Tumour Syndrome.
{Author}: Bellido V;Larrañaga I;Guimón M;Martinez-Conde R;Eguia A;Perez de Nanclares G;Castaño L;Gaztambide S;
{Journal}: Endocr Pathol
{Volume}: 27
{Issue}: 2
{Year}: Jun 2016
{Factor}: 4.056
{DOI}: 10.1007/s12022-016-9427-6
{Abstract}: Hyperparathyroidism-jaw tumour syndrome (HPT-JT) is a rare variant of familial hyperparathyroidism, characterized by primary hyperparathyroidism (PHPT) due to one or multiple parathyroid adenomas, and benign tumours of the mandible and maxilla. It has an autosomal dominant pattern of inheritance, and is associated with mutations that deactivate the cell division cycle protein 73 homolog (CDC73) gene, also known as hyperparathyroidism 2 (HRPT2), located on the long arm of chromosome 1, that encodes for the tumour suppressor protein parafibromin. In the majority of cases, PHPT is the presenting symptom, but up to 30 % of HPT-JT cases initially present with an ossifying fibroma of the maxillofacial bones. HPT-JT may result in severe hypercalcemia-related complications and an elevated risk of parathyroid carcinoma. For this reason, early identification of the disease is important. We present the case of a 23-year-old woman who was found to have jaw tumours and was later diagnosed with PHPT. Genetic analysis revealed a novel mutation in exon 1 of CDC73. This report contributes to the understanding of the genetics of this rare syndrome. It also highlights the fact that HPT-JT should be considered and CDC73 mutation analysis should be performed in cases of early-onset PHPT associated with ossifying fibromas of the jaw.